Sept 2005 FINAL- Formatted

The UK government has estimated its National Health Service saves £60m a year from the practice, while the York Health Economics Consortium, in a study sponsored by the European parallel traders' association, put annual savings at €635m in the EU and €342m in the UK. [...] Rosenberg said, "It is very helpful to be developing drugs in close consultation with the doctors who are going to be using the drugs." Benefits to community On the northwest edge of Philadelphia's booming suburbs, just a few miles from Amish country, Genevieve Coale has watched the growing concentration of the world's pharmaceutical industry in the United States transform her community. [...] In the region, the drug industry, made up of both American- and European-headquartered firms, is by far the most important manufacturing sector, a business worth more than $5 billion a year that also is the most technology-intensive and the most productive, in terms of output per worker. [...] The Medicines and Healthcare Products Regulatory Agency (MHRA), which polices the licensing and supply of medicines in Britain, says the country has the best regulations in the world but that no system is impenetrable. [...] Moreover, Peter Allgeier, the deputy trade representative, said a specific provision in the agreement says that "not withstanding any of the provisions in the agreement, this does not diminish the country’s ability to meet their public health needs." He said, "If there is a public health need, or a public health crisis, is there anything in the agreement that prevents countries from meeting their.